Nirsevimab and Hospitalization for RSV Bronchiolitis.
Zein AssadAnne-Sophie RomainCamille AupiaisMickaël ShumCécile SchrimpfMathie LorrotHarriet CorvolBlandine PrevostCharlène FerrandizAnna GiolitoZaba ValtuilleMatthieu BendavidJérémie F CohenJulie ToubianaLoïc de PontualCamille F DelandeMichael LevyPerrine SeeRobert CohenCorinne LevyFrançois AngoulvantLéa LenglartMaud Gits-MuselliValérie BiranKadiatou DialloOluwafunmilola AlemedeMohamed M El HebilXavier DurrmeyerGéraldine LabouretNatacha CasanovasBenjamin HallakOlympe MaréchalCamille JungCamille BréhinNaïm OuldaliPublished in: The New England journal of medicine (2024)
In a real-world setting, nirsevimab therapy was effective in reducing the risk of hospitalized RSV-associated bronchiolitis. (Funded by the National Agency for AIDS Research-Emerging Infectious Disease and others; ENVIE ClinicalTrials.gov number, NCT06030505.).